查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1438239

2030 年卡波西氏肉瘤市场预测：按类型、诊断方法、治疗方法、最终用户和地区进行的全球分析

Kaposi Sarcoma Market Forecasts to 2030 - Global Analysis By Type, Diagnostic Method, Treatment Modality, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2023 年全球卡波西氏肉瘤市场规模为 1.0869 亿美元，预计 2030 年将达到 1.5092 亿美元，预测期内复合年增长率为 4.8%。

卡波西氏肉瘤 (KS) 是一种罕见的癌症，其特征是血管异常生长以及皮肤、黏膜和内臟器官的病变。它是由人类疱疹病毒 8 型 (HHV-8) 感染引起的，通常影响免疫系统较弱的人，例如爱滋病毒/爱滋病患者和接受免疫抑制治疗的人。早期诊断和有效治疗对于改善卡波西氏肉瘤患者的预后至关重要。

2022 年 3 月发表在《临床癌症研究》上的一项研究得出结论，Pomalidomide是一种安全有效的免化疗药物，用于治疗感染和未感染 HIV 患者的卡波西氏肉瘤。

爱滋病毒/爱滋病流行

HIV/爱滋病会削弱免疫系统，使人们更容易罹患卡波西氏肉瘤，这是一种与人类疱疹病毒 8 (HHV-8) 感染相关的癌症。随着全球爱滋病毒/爱滋病盛行率的增加，卡波西氏肉瘤的发生率也随之增加，特别是在抗逆转录病毒治疗机会有限的地区。盛行率的上升推动了对卡波西氏肉瘤早期检测、诊断和治疗的需求，导致针对爱滋病毒/爱滋病感染者疾病管理的治疗性介入、诊断工具和支持性护理服务市场不断增长，这激励着我。

治疗的副作用

卡波西氏肉瘤的治疗方法，包括化疗、放射线治疗和免疫疗法，可能会引起严重的副作用。这些会导致噁心、呕吐、脱髮和骨髓抑制，损害患者的生活品质和治疗依从性。这些副作用不仅影响患者的健康，还会抑制治疗顺从性并需要调整剂量或停药。

诊断的进展

诊断的进步极大地促进了早期发现和开始治疗。免疫组织化学和分子生物学测试等诊断技术的改进可以更准确、更及时地识别卡波西氏肉瘤病变，从而实现早期疗育并改善患者预后。此外，生物标记研究的进步将促进风险分层和个人化治疗方法。此类诊断创新透过增加对诊断工具、影像设备以及与卡波西氏肉瘤诊断和监测相关的辅助服务的需求来扩大市场。

治疗费用高

卡波西氏肉瘤的高治疗费用主要是由于治疗方法复杂且往往时间较长。这些治疗方法包括化疗、放射线治疗、标靶治疗和免疫治疗，这些治疗通常很昂贵且需要专门的医学知识。此外，控制治疗相关副作用的支持性护理进一步增加了整体治疗成本。高昂的治疗成本限制了人们获得医疗保健的机会，尤其是在医疗资源有限的地区，并阻碍了市场的成长。

COVID-19 的影响

COVID-19 的爆发对卡波西氏肉瘤市场产生了多方面的影响。因疫情而不堪负荷的医疗保健系统转移了非新冠相关疾病的资源，导致卡波西肉瘤的诊断和治疗延误。经济不确定性和医疗资源的重新分配也影响了研究经费和药物开发工作。结果，大流行加剧了卡波西肉瘤管理方面的现有挑战，并透过扰乱患者治疗途径和研究工作阻碍了市场成长。

预计在预测期内，流行的卡波西氏肉瘤部分将是最大的

流行的卡波西肉瘤部分预计将经历良好的增长。流行性卡波西氏肉瘤是一种在爱滋病毒/爱滋病流行期间出现的卡波西氏肉瘤，主要影响免疫力缺乏的个体。它是由人类疱疹病毒 8 型 (HHV-8) 感染引起的，其特征是皮肤、黏膜和内臟器官出现多发性且通常广泛的病变。爱滋病毒/爱滋病的流行，特别是在高流行地区，是导致地方性 KS 病例增加的重要原因。

预计化疗领域在预测期内复合年增长率最高。

化疗领域在预测期内将出现最高的复合年增长率。化疗是卡波西氏肉瘤的基本治疗方法，特别是进行性或侵袭性病例。最常使用的化疗药物包括微脂体细胞週期蛋白、紫杉醇和长春花生物碱。化疗的目的是缩小或稳定 KS 肿瘤、缓解症状并提高生活品质。化疗方案已被证明可以延长 KS 患者的生存期，从而加速了这群人的成长。

比最大的地区

预计亚太地区在预测期内将占据最大的市场占有率。印度和泰国等国家建立了强大的医疗基础设施和研究能力。在该地区，政府、医疗机构和製药公司之间的合作正在改善患者的治疗效果。此外，加强努力扩大抗逆转录病毒治疗的可及性并提高人们对爱滋病毒/爱滋病和相关癌症的认识，正在为亚太地区的卡波西氏肉瘤市场创造成长机会。

复合年增长率最高的地区：

由于爱滋病毒/爱滋病的高发病率、先进的医疗基础设施以及对该疾病的认识不断提高，预计北美在预测期内将呈现最高的复合年增长率。该地区拥有完善的製药和生物技术产业，因此可以提供卡波西氏肉瘤的先进治疗方案和临床试验。此外，支持性的政府政策、大量的研究经费以及提高爱滋病毒/爱滋病意识和预防的努力正在进一步推动市场成长。

免费客製化服务

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场参与者的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 调查来源
    • 主要调查来源
    • 二次调查来源
    • 先决条件

第三章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 最终用户分析
  • 新兴市场
  • 新型冠状病毒感染疾病（COVID-19）的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第五章全球卡波西氏肉瘤市场：按类型

  • 经典卡波西氏肉瘤
  • 地方性卡波西氏肉瘤
  • 流行性卡波西氏肉瘤
  • 免疫抑制相关的卡波西氏肉瘤
  • 晚期卡波西氏肉瘤
  • 播散性卡波西氏肉瘤
  • 其他类型

第六章全球卡波西氏肉瘤市场：依诊断方法

  • 组织病理学
  • 免疫组织化学 (IHC)
  • 聚合酵素链锁反应(PCR)
  • 切片检查
  • 其他诊断方法

第七章全球卡波西氏肉瘤市场：依治疗方法分类

  • 抗逆转录病毒治疗（ART）
  • 化疗
  • 免疫疗法
  • 放射治疗
  • 标靶治疗
  • 其他治疗方法

第八章全球卡波西氏肉瘤市场：依最终用户分类

  • 医院和诊所
  • 癌症研究所
  • 门诊手术中心
  • 家庭保健
  • 其他最终用户

第九章全球卡波西氏肉瘤市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲

第10章 主要进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十一章 公司简介

  • Abbott Laboratories
  • AbbVie Inc
  • Biogen Inc
  • Bio-Rad Laboratories
  • Cornell Engineering
  • Celgene Corporation
  • Cipla Limited
  • Eli Lilly and Company
  • Genentech Inc
  • Johnson & Johnson
  • Leo Pharma A/S
  • Merck & Co. Inc
  • Novartis International AG
  • Pfizer Inc
  • Roche Holding AG
  • Siemens Healthineers
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical
  • Thermo Fisher Scientific Inc
  • Vertex Pharmaceuticals Incorporated
Product Code: SMRC25208

According to Stratistics MRC, the Global Kaposi Sarcoma Market is accounted for $108.69 million in 2023 and is expected to reach $150.92 million by 2030 growing at a CAGR of 4.8% during the forecast period. Kaposi Sarcoma (KS) is a rare cancer characterized by abnormal growth of blood vessels and lesions on the skin, mucous membranes, and internal organs. It is caused by infection with human herpesvirus 8 (HHV-8), often affecting individuals with compromised immune systems, such as those with HIV/AIDS or undergoing immunosuppressive therapy. Early diagnosis and effective management are crucial for improving outcomes in patients with Kaposi Sarcoma.

According to the study published in Clinical Cancer Research in March 2022, the study concluded that Pomalidomide is a safe and effective chemotherapy-sparing medication for the treatment of Kaposi sarcoma in people with or without HIV.

Market Dynamics:

Driver:

Growing prevalence of HIV/AIDS

HIV/AIDS weakens the immune system, making individuals more susceptible to developing kaposi sarcoma, a cancer associated with human herpesvirus 8 (HHV-8) infections. As HIV/AIDS prevalence raises globally, particularly in regions with limited access to antiretroviral therapy, the incidence of Kaposi sarcoma increases accordingly. This heightened prevalence drives demand for early detection, diagnosis, and treatment of Kaposi sarcoma, fueling market growth for therapeutic interventions, diagnostic tools, and supportive care services aimed at managing the disease in HIV/AIDS-affected populations.

Restraint:

Side effects of therapy

The therapies for kaposi sarcoma, including chemotherapy, radiation therapy, and immunotherapy, can lead to significant side effects. They may cause nausea, vomiting, hair loss, and bone marrow suppression, compromising patients' quality of life and treatment adherence. These side effects not only impact patient well-being but also deter treatment compliance and may necessitate dose adjustments or discontinuation, thereby limiting the market growth by reducing patient acceptance and adoption of kaposi sarcoma therapies.

Opportunity:

Advancements in diagnosis

Advancements in diagnosis significantly enhance early detection and treatment initiation. Improved diagnostic techniques such as immunohistochemistry and molecular testing enable more accurate and timely identification of kaposi sarcoma lesions, leading to earlier interventions and better patient outcomes. Additionally, advances in biomarker research facilitate risk stratification and personalized therapy approaches. These diagnostic innovations expand the market by increasing the demand for diagnostic tools, imaging equipment, and ancillary services related to kaposi sarcoma diagnosis and monitoring.

Threat:

High cost of treatment

Kaposi Sarcoma's high cost of treatment is primarily attributed to the complex and often prolonged therapeutic regimens involved. These regimens may include chemotherapy, radiation therapy, and targeted or immunotherapy, which are costly to administer and often require specialized medical expertise. Additionally, supportive care to manage treatment-related side effects further adds to the overall treatment expenses. The high cost of treatment can limit access to care, particularly in regions with limited healthcare resources, thereby hampering market growth.

Covid-19 Impact

The covid-19 pandemic has had a multifaceted impact on the kaposi sarcoma market. Healthcare systems strained by the pandemic diverted resources away from non-covid-related conditions, leading to delays in Kaposi sarcoma diagnosis and treatment. Economic uncertainties and healthcare resource reallocations also affected research funding and drug development efforts. Consequently, the pandemic exacerbated existing challenges in kaposi sarcoma management and impeded market growth by disrupting patient care pathways and research endeavours.

The epidemic kaposi sarcoma segment is expected to be the largest during the forecast period

The epidemic kaposi sarcoma segment is estimated to have a lucrative growth. Epidemic Kaposi Sarcoma refers to a form of KS that emerged during the HIV/AIDS epidemic, predominantly affecting immunocompromised individuals. It is caused by human herpes virus 8 (HHV-8) infections and is characterized by the development of multiple, often widespread, lesions on the skin, mucous membranes, and internal organs. The HIV/AIDS epidemic, particularly in regions with high prevalence, significantly contributed to the rise of epidemic KS cases.

The chemotherapy segment is expected to have the highest CAGR during the forecast period

The chemotherapy segment is anticipated to witness the highest CAGR growth during the forecast period. Chemotherapy is a cornerstone treatment for Kaposi Sarcoma, particularly in advanced or aggressive cases. The most commonly used chemotherapy agents include liposomal anthracyclines, paclitaxel, and vinca alkaloids. Chemotherapy aims to shrink or stabilize KS tumors, alleviate symptoms, and improve quality of life. Chemotherapy regimens have been shown to extend survival in KS patients which is accelerating the segment growth.

Region with largest share:

Asia Pacific is projected to hold the largest market share during the forecast period. Countries like India and Thailand have established strong healthcare infrastructure and research capabilities. Collaboration between governments, healthcare organizations and pharmaceutical companies in the region are improving patient outcomes. Further, increasing efforts to expand access to antiretroviral therapy, and raise awareness about HIV/AIDS and related cancers offer growth opportunities for the Kaposi Sarcoma market in Asia Pacific.

Region with highest CAGR:

North America is projected to have the highest CAGR over the forecast period, owing to the high prevalence of HIV/AIDS, advanced healthcare infrastructure, and increasing awareness about the disease. The region's well-established pharmaceutical and biotechnology industries contribute to the availability of advanced treatment options and clinical trials for Kaposi Sarcoma. Additionally, supportive government policies, robust research funding, and initiatives promoting HIV/AIDS awareness and prevention further bolster market growth.

Key players in the market

Some of the key players profiled in the Kaposi Sarcoma Market include Abbott Laboratories, AbbVie Inc, Biogen Inc, Bio-Rad Laboratories, Cornell Engineering, Celgene Corporation, Cipla Limited, Eli Lilly and Company, Genentech Inc, Johnson & Johnson, Leo Pharma A/S, Merck & Co. Inc, Novartis International AG, Pfizer Inc, Roche Holding AG, Siemens Healthineers, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical, Thermo Fisher Scientific Inc and Vertex Pharmaceuticals Incorporated.

Key Developments:

In August 2022, Researchers at Cornell Engineering and Weill Cornell Medicine designed a portable diagnostic device that has been deployed in clinical tests in Uganda to identify cases of Kaposi sarcoma. This common yet difficult-to-detect cancer often signals the presence of HIV infection.

Types Covered:

  • Classic Kaposi Sarcoma
  • Endemic Kaposi Sarcoma
  • Epidemic Kaposi Sarcoma
  • Immunosuppression-Associated Kaposi Sarcoma
  • Latrogenic Kaposi Sarcoma
  • Disseminated Kaposi Sarcoma
  • Other Types

Diagnostic Methods Covered:

  • Histopathology
  • Immunohistochemistry (IHC)
  • Polymerase Chain Reaction (PCR)
  • Biopsy
  • Other Diagnostic Methods

Treatment Modalities Covered:

  • Antiretroviral Therapy (ART)
  • Chemotherapy
  • Immunotherapy
  • Radiation Therapy
  • Targeted Therapy
  • Other Therapies

End Users Covered:

  • Hospitals & Clinics
  • Cancer Research Institutions
  • Ambulatory Surgical Centers
  • Home Healthcare
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Kaposi Sarcoma Market, By Type

  • 5.1 Introduction
  • 5.2 Classic Kaposi Sarcoma
  • 5.3 Endemic Kaposi Sarcoma
  • 5.4 Epidemic Kaposi Sarcoma
  • 5.5 Immunosuppression-Associated Kaposi Sarcoma
  • 5.6 Latrogenic Kaposi Sarcoma
  • 5.7 Disseminated Kaposi Sarcoma
  • 5.8 Other Types

6 Global Kaposi Sarcoma Market, By Diagnostic Method

  • 6.1 Introduction
  • 6.2 Histopathology
  • 6.3 Immunohistochemistry (IHC)
  • 6.4 Polymerase Chain Reaction (PCR)
  • 6.5 Biopsy
  • 6.6 Other Diagnostic Methods

7 Global Kaposi Sarcoma Market, By Treatment Modality

  • 7.1 Introduction
  • 7.2 Antiretroviral Therapy (ART)
  • 7.3 Chemotherapy
  • 7.4 Immunotherapy
  • 7.5 Radiation Therapy
  • 7.6 Targeted Therapy
  • 7.7 Other Therapies

8 Global Kaposi Sarcoma Market, By End User

  • 8.1 Introduction
  • 8.2 Hospitals & Clinics
  • 8.3 Cancer Research Institutions
  • 8.4 Ambulatory Surgical Centers
  • 8.5 Home Healthcare
  • 8.6 Other End Users

9 Global Kaposi Sarcoma Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Abbott Laboratories
  • 11.2 AbbVie Inc
  • 11.3 Biogen Inc
  • 11.4 Bio-Rad Laboratories
  • 11.5 Cornell Engineering
  • 11.6 Celgene Corporation
  • 11.7 Cipla Limited
  • 11.8 Eli Lilly and Company
  • 11.9 Genentech Inc
  • 11.10 Johnson & Johnson
  • 11.11 Leo Pharma A/S
  • 11.12 Merck & Co. Inc
  • 11.13 Novartis International AG
  • 11.14 Pfizer Inc
  • 11.15 Roche Holding AG
  • 11.16 Siemens Healthineers
  • 11.17 Takeda Pharmaceutical Company Limited
  • 11.18 Teva Pharmaceutical
  • 11.19 Thermo Fisher Scientific Inc
  • 11.20 Vertex Pharmaceuticals Incorporated

List of Tables

  • Table 1 Global Kaposi Sarcoma Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Kaposi Sarcoma Market Outlook, By Type (2021-2030) ($MN)
  • Table 3 Global Kaposi Sarcoma Market Outlook, By Classic Kaposi Sarcoma (2021-2030) ($MN)
  • Table 4 Global Kaposi Sarcoma Market Outlook, By Endemic Kaposi Sarcoma (2021-2030) ($MN)
  • Table 5 Global Kaposi Sarcoma Market Outlook, By Epidemic Kaposi Sarcoma (2021-2030) ($MN)
  • Table 6 Global Kaposi Sarcoma Market Outlook, By Immunosuppression-Associated Kaposi Sarcoma (2021-2030) ($MN)
  • Table 7 Global Kaposi Sarcoma Market Outlook, By Latrogenic Kaposi Sarcoma (2021-2030) ($MN)
  • Table 8 Global Kaposi Sarcoma Market Outlook, By Disseminated Kaposi Sarcoma (2021-2030) ($MN)
  • Table 9 Global Kaposi Sarcoma Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 10 Global Kaposi Sarcoma Market Outlook, By Diagnostic Method (2021-2030) ($MN)
  • Table 11 Global Kaposi Sarcoma Market Outlook, By Histopathology (2021-2030) ($MN)
  • Table 12 Global Kaposi Sarcoma Market Outlook, By Immunohistochemistry (IHC) (2021-2030) ($MN)
  • Table 13 Global Kaposi Sarcoma Market Outlook, By Polymerase Chain Reaction (PCR) (2021-2030) ($MN)
  • Table 14 Global Kaposi Sarcoma Market Outlook, By Biopsy (2021-2030) ($MN)
  • Table 15 Global Kaposi Sarcoma Market Outlook, By Other Diagnostic Methods (2021-2030) ($MN)
  • Table 16 Global Kaposi Sarcoma Market Outlook, By Treatment Modality (2021-2030) ($MN)
  • Table 17 Global Kaposi Sarcoma Market Outlook, By Antiretroviral Therapy (ART) (2021-2030) ($MN)
  • Table 18 Global Kaposi Sarcoma Market Outlook, By Chemotherapy (2021-2030) ($MN)
  • Table 19 Global Kaposi Sarcoma Market Outlook, By Immunotherapy (2021-2030) ($MN)
  • Table 20 Global Kaposi Sarcoma Market Outlook, By Radiation Therapy (2021-2030) ($MN)
  • Table 21 Global Kaposi Sarcoma Market Outlook, By Targeted Therapy (2021-2030) ($MN)
  • Table 22 Global Kaposi Sarcoma Market Outlook, By Other Therapies (2021-2030) ($MN)
  • Table 23 Global Kaposi Sarcoma Market Outlook, By End User (2021-2030) ($MN)
  • Table 24 Global Kaposi Sarcoma Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
  • Table 25 Global Kaposi Sarcoma Market Outlook, By Cancer Research Institutions (2021-2030) ($MN)
  • Table 26 Global Kaposi Sarcoma Market Outlook, By Ambulatory Surgical Centers (2021-2030) ($MN)
  • Table 27 Global Kaposi Sarcoma Market Outlook, By Home Healthcare (2021-2030) ($MN)
  • Table 28 Global Kaposi Sarcoma Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.